Search

Exelixis Inc

Abierto

SectorSanidad

54.53 1

Resumen

Variación precio

24h

Actual

Mínimo

53.3

Máximo

54.1

Métricas clave

By Trading Economics

Ingresos

1.6M

212M

Ventas

18M

629M

P/B

Media del Sector

16.453

57.371

BPA

0.82

Margen de beneficios

33.729

Empleados

1,077

EBITDA

-12M

263M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

-3.99% downside

Dividendos

By Acuity

Próximas Ganancias

3 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-876M

13B

Apertura anterior

53.53

Cierre anterior

54.53

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

147 / 340 Clasificación en Healthcare

Exelixis Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 ago 2026, 20:06 UTC

Exelixis Inc shares are higher today, continuing a trend since Thursday's close. Broader biotechnology sector gains may be contributing to the movement.

20 ago 2026, 23:36 UTC

Exelixis Inc's shares are higher in after-market trading, reflecting notable strength despite no specific news to explain the price action.

19 ago 2026, 19:36 UTC

News

BMO Capital initiated coverage on Exelixis Inc with a Market Perform rating and a price target of $54. Shares are trading higher today.

18 ago 2026, 23:56 UTC

News

Exelixis shares are lower in after-market hours following BMO's Market Perform rating. Broader market pressures from rising bond yields also weigh on the stock.

13 ago 2026, 19:46 UTC

Exelixis Inc's shares are higher Thursday, supported by positive investor sentiment despite a slight pullback from earlier gains. Initial jobless claims rose to 209k.

12 ago 2026, 19:51 UTC

News

Exelixis Inc shares are lower amid an investigation for potential securities law violations and a revenue shortfall of $628.7 million in Q2.

11 ago 2026, 23:51 UTC

Exelixis Inc shares are lower in after-market hours, continuing a downward trend since Tuesday's close amid notable volatility and market anticipation of the CPI report.

10 ago 2026, 23:01 UTC

News

Exelixis shares are lower in after-market trading amid scrutiny over a potential securities fraud investigation and lowered full-year revenue guidance.

8 ago 2026, 00:01 UTC

Exelixis Inc shares are trading lower in after-market hours, amid weak overall market conditions and unusual trading patterns.

7 ago 2026, 21:01 UTC

Exelixis Inc shares are lower in after-market trading, reflecting notable weakness and remaining below the 20-day moving average. No specific news was identified.

6 ago 2026, 23:31 UTC

Exelixis Inc's shares are higher in after-market hours, recovering from an earlier dip. The stock remains below its 20-day moving average.

5 ago 2026, 23:02 UTC

News

Exelixis Inc. shares are lower in after-market trading following second-quarter results that missed revenue expectations and a cut to full-year guidance.

4 ago 2026, 19:16 UTC

Exelixis Inc shares are higher today, reaching a peak above Monday's close. The broader market is supported by a drop in crude oil prices.

3 ago 2026, 23:02 UTC

Exelixis Inc shares are lower in after-market trading, continuing a decline since Monday's close amid no specific news to explain the movement.

31 jul 2026, 23:36 UTC

Exelixis Inc shares are lower in after-market trading, influenced by broader market weakness amid a decline in Apple shares following disappointing guidance.

30 jul 2026, 17:56 UTC

Exelixis shares are higher during Thursday's session, gradually improving from an early dip. No specific company news was identified to explain the movement.

29 jul 2026, 19:37 UTC

Exelixis Inc. shares are trading lower today amid high volume and broader market dynamics, including a significant surge in oil prices raising inflation concerns.

28 jul 2026, 20:06 UTC

Exelixis Inc is trading higher amid a strong Biotechnology sector. The stock remains above its 20-day moving average, indicating market strength.

27 jul 2026, 18:46 UTC

Exelixis Inc shares are higher today, reflecting broader market trends amid a notable decline in crude oil prices. The stock peaked earlier in the session.

24 jul 2026, 19:46 UTC

Exelixis Inc shares are lower today, continuing a decline since Thursday. Broader market volatility is influenced by fluctuations in oil prices and U.S. tariffs.

22 jul 2026, 21:26 UTC

News

Exelixis Inc will release its Q2 2026 financial results on August 5. Shares are trading higher after the announcement, reflecting positive investor sentiment.

Comparación entre iguales

Cambio de precio

Exelixis Inc previsión

Precio Objetivo

By TipRanks

-3.99% descenso

Estimación a 12 Meses

Media 51.92 USD  -3.99%

Máximo 64 USD

Mínimo 41 USD

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Exelixis Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

15 ratings

4

Comprar

10

Mantener

1

Vender

Sentimiento

By Acuity

147 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Exelixis Inc

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
help-icon Live chat